• 1
    Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 79116.
  • 2
    Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117: 99105.
  • 3
    Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000; 21: 7380.
  • 4
    Feltrin KL, Patterson M, Ghatei MA, et al. Effect of fatty acid chain length on suppression of ghrelin and stimulation of PYY, GLP-2 and PP secretion in healthy men. Peptides 2006; 27: 1638–1643.
  • 5
    Tappenden K, Kelly A. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes. Dig Dis Sci 1998; 43: 1526.
  • 6
    Bartholome AL, Albin DM, Baker DH, Holst JJ, Tappenden KA. Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. JPEN J Parenter Enteral Nutr 2004; 28: 21022; discussion: 222–3.
  • 7
    Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 21809.
  • 8
    Reimann F, Williams L, Silva Xavier G, et al. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 2004; 47: 1592.
  • 9
    Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 38690.
  • 10
    Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000; 85: 28848.
  • 11
    Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 122431.
  • 12
    Thulesen J, Hartmann B, Orskov C, Jeppesen PB, Holst JJ, Poulsen SS. Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2. Peptides 2000; 21: 15117.
  • 13
    Hartmann B, Thulesen J, Kissow H, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000; 141: 401320.
  • 14
    Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997; 138: 483743.
  • 15
    Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96: 156973.
  • 16
    Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 74455.
  • 17
    Henriksen DB, Alexandersen P, Karsdal M, et al. Dose-related effects of nocturnal bone remodelling processes by subcutaneous GLP-2 in postmenopausal women. Osteoporos Int 2004; 15 (Suppl. 1): S91.
  • 18
    Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 15064.
  • 19
    Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124: 10512.
  • 20
    Martin GR, Wallace LE, Hartmann B, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005; 288: G4318.
  • 21
    Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 3706.
  • 22
    Caddy GR, Ardill JE, Fillmore D, et al. Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease. Eur J Gastroenterol Hepatol 2006; 18: 195202.
  • 23
    Niinikoski H, Stoll B, Guan X, et al. Onset of small intestinal atrophy is associated with reduced intestinal blood flow in TPN-fed neonatal piglets. J Nutr 2004; 134: 146774.
  • 24
    Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol 2000; 35: 5227.
  • 25
    Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005; 128: 134053.
  • 26
    Perez A, Duxbury M, Rocha FG, et al. Glucagon-like peptide 2 is an endogenous mediator of postresection intestinal adaptation. JPEN J Parenter Enteral Nutr 2005; 29: 97101.
  • 27
    Litvak DA, Hellmich MR, Evers BM, Banker NA, Townsend CM Jr. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J Gastrointest Surg 1998; 2: 14650.
  • 28
    Ghatei MA, Goodlad RA, Taheri S, et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 2001; 46: 125563.
  • 29
    Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 1997; 273: G125262.
  • 30
    Petersen YM, Elnif J, Schmidt M, Sangild PT. Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets. Pediatr Res 2002; 52: 498503.
  • 31
    Kitchen PA, Fitzgerald AJ, Goodlad RA, et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol Gastrointest Liver Physiol 2000; 278: G4258.
  • 32
    Howard A, Goodlad RA, Walters JR, Ford D, Hirst BH. Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by TPN is reversed by GLP-2. J Nutr 2004; 134: 295764.
  • 33
    Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130: 4454.
  • 34
    Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998; 33: 82832.
  • 35
    Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39: 3538.
  • 36
    Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 80615.
  • 37
    Kouris GJ, Liu Q, Rossi H, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001; 181: 5715.
  • 38
    Cameron HL, Yang PC, Perdue MH. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 2003; 284: G90512.
  • 39
    Cameron HL, Perdue MH. Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 2005; 314: 21420.
  • 40
    Chance WT, Sheriff S, McCarter F, Ogle C. Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats. J Burn Care Rehabil 2001; 22: 13643.
  • 41
    Stephens J, Stoll B, Cottrell J, Chang X, Helmrath M, Burrin DG. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol 2006; 290: R2839.
  • 42
    Guan X, Stoll B, Lu X, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125: 13647.
  • 43
    Kitchen PA, Goodlad RA, Fitzgerald AJ, et al. Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. JPEN J Parenter Enteral Nutr 2005; 29: 24854.
  • 44
    Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006; 131: 589605.
  • 45
    Shin ED, Drucker DJ, Brubaker PL. Glucagon-like peptide 2: an update. Curr Opin Endocrinol Diabetes 2005; 12: 6371.
  • 46
    Sinclair EM, Drucker DJ. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology (Bethesda) 2005; 20: 35765.
  • 47
    Drucker D. http://www.glucagon.comLast accessed October 2006.
  • 48
    Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999; 45: 55963.
  • 49
    In NPS Allelix Corp. Safety and Efficacy Study of Teduglutide in Subjects with Short Bowel Syndrome. (NCT00081458) Last accessed October 2006.
  • 50
    L'Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003; 306: 34754.
  • 51
    Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 2004; 39: 44852; discussion 448–52.
  • 52
    Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000; 35: 84751.
  • 53
    Buchman K, Shnaidman J. Effect of teduglutide on patients with moderate–severe Crohn's disease after 8 weeks of therapy: a prospective, double-blind, placebo-controlled trial. Gastroenterology 2006; 131: 94950.
  • 54
    Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34: 1407.
  • 55
    Haderslev KV, Jeppesen PB, Hartmann B, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37: 3928.
  • 56
    Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 1997; 273: G55963.
  • 57
    Yamazaki K, Yasuda N, Inoue T, et al. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 2004; 488: 2138.
  • 58
    Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37: 385400.
  • 59
    Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol Endocrinol Metab 1999; 277: E93747.
  • 60
    Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 2005; 19: 45973.
  • 61
    Thulesen J, Hartmann B, Hare KJ, et al. (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004; 2: 114550.
  • 62
    Guan L, Gong D, Tian N, Zou Y. Uncoupling protein 2 involved in protection of glucagon-like peptide 2 in small intestine with ischemia–reperfusion injury in mice. Dig Dis Sci 2005; 50: 55460.
  • 63
    Rocha FG, Shen KR, Jasleen J, et al. Glucagon-like peptide-2: divergent signaling pathways. J Surg Res 2004; 121: 512.
  • 64
    Chance WT, Sheriff S, Foley-Nelson T, Thomas I, Balasubramaniam A. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 2000; 37: 21522.